Filter Results
Clinical Studies
Results filtered:Study status:
Contact Us for the Latest Status
Closed for Enrollment
Contact Us for the Latest Status
Closed for Enrollment
-
A Phase 1b Multicenter, Randomized, Double-Blind, Placebo-Controlled Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of DISC-0974 In Participants With Non-Dialysis Dependent Chronic Kidney Disease And Anemia
Rochester, Minn.
Th purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult participants with Non-Dialysis Dependent Chronic Kidney Disease and Anemia.
-
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating The Efficacy And Safety Of Remdesivir In Participants With Severely Reduced Kidney Function Who Are Hospitalized For COVID-19
Rochester, Minn.,
Jacksonville, Fla.
The primary objective of this study is to evaluate whether remdesivir (RDV, GS-5734™) reduces the composite risk of death or invasive mechanical ventilation (IMV) through Day 29 in participants with severely reduced kidney function who are hospitalized for coronavirus disease 2019 (COVID-19).
-
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study To Assess The Efficacy And Safety Of Baxdrostat In Participants With Uncontrolled Hypertension On Two Or More Medications Including Participants With Resistant Hypertension
Scottsdale/Phoenix, Ariz.,
Rochester, Minn.
The purpose of this study is to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally, on the reduction of systolic blood pressure in approximately 720 participants aged ≥ 18 years with hypertension, despite a stable regimen of 2 antihypertensive agents at baseline, one of which is a diuretic (uncontrolled hypertension); or ≥ 3 antihypertensive agents at baseline, one of which is a diuretic (treatment-resistant hypertension).
.